Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
RESEARCH TOOLSreports
Holding MLTX?
Track your performance easily
MLTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$37.55 - $64.98
Previous Close$51.88
Volume192.79K
Average Volume (3M)284.28K
Market Cap
$3.32B
Enterprise Value$2.83B
Total Cash (Recent Filing)$493.92M
Total Debt (Recent Filing)$3.38M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 24, 2025EPS Estimate
-$0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding63,905,198
10 Day Avg. Volume235,626
30 Day Avg. Volume284,282
Standard Deviation0.20
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)6.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-32.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-38.00
Forecast
1Y Price Target
$75.50Price Target Upside44.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
MoonLake Immunotherapeutics News
PremiumCompany Announcements
MoonLake Immunotherapeutics Announces Board Changes and Incentives
PremiumCompany Announcements
MoonLake Immunotherapeutics Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical ExecutionAnalyst highlights the strong clinical execution of MLTX, focusing on their lead asset sonelokimab across multiple immuno-inflammatory diseases in dermatology and rheumatology.
Financial StabilityMoonLake ended 3Q24 with $493.9M in cash, cash equivalents and short-term marketable securities, which is expected to be sufficient to fund operations through 2026 and past completion of clinical development for SLK in HS.
Market PotentialThe US HS market could eclipse $10B, driven by more effective and durable therapies becoming available to patients.
Bears Say
Clinical TrialsInability to advance SLK in pivotal trials in a timely fashion and failure of SLK to show compelling clinical efficacy in pivotal trials.
Financial PerformanceThe relatively modest difference in net loss was principally due to higher-than-anticipated R&D spending.
Market CompetitionThe projected $15bn+ total HS opportunity for 2035 probably shifts more focus onto the performance of marketed competitor drugs in HS and any additional commentary from competitor management teams.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $37.55 and its highest was $64.98 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
Currently, no data Available
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Mar 24, 2025 which is in 92 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Nov 07, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.435 by -$0.125.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -$0.6.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 63,063,930 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.435. Following the earnings report the stock price went down -1.573%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Among the largest hedge funds holding MoonLake Immunotherapeutics’s share is Woodline Partners LP. It holds MoonLake Immunotherapeutics’s shares valued at 12M.
---
MoonLake Immunotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.50 (44.72% Upside)
$75.50 (44.72% Upside)
Blogger Sentiment
Neutral
MLTX Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 5.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $109.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.8%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.12%
12-Months-Change
Fundamentals
Return on Equity
-17.69%
Trailing 12-Months
Asset Growth
3.60%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
Helix Acquisition Corp is a blank check company.
---
MLTX Stock 12 Month Forecast
Average Price Target
$75.50
▲(44.72% Upside)
Technical Analysis
Best Analysts Covering MLTX
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+13.27%
reiterated a buy rating last month
Copying Serge Belanger's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +13.27% per trade.
---